FMOC-D-2-二氢茚基甘氨酸 | 205526-40-5

• 物质功能分类: 生物化工 - 氨基酸及其衍生物 - 甘氨酸类衍生物
• 分子结构分类: 有机化合物 - 苯类化合物 - 芴
• 中文名称: FMOC-D-2-二氢茚基甘氨酸
• 中文别名: Fmoc-D-2-二氢茚基甘氨酸；Fmoc-D-2-茚满甘氨酸
• 英文名称: Fmoc-D-Igl-OH
• 英文别名: Fmoc-D-β-indanylglycine；(R)-2-((((9H-Fluoren-9-yl)methoxy)carbonyl)amino)-2-(2,3-dihydro-1H-inden-2-yl)acetic acid；(2R)-2-(2,3-dihydro-1H-inden-2-yl)-2-(9H-fluoren-9-ylmethoxycarbonylamino)acetic acid
• CAS: 205526-40-5
• 化学式: C₂₆H₂₃NO₄
• 分子量: 413.473
• InChiKey: PLYYQWWELYJSEB-XMMPIXPASA-N

物化性质

• 沸点：
  656.8±43.0 °C(Predicted)
• 密度：
  1.298±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  4.9
• 重原子数：
  31
• 可旋转键数：
  6
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.23
• 拓扑面积：
  75.6
• 氢给体数：
  2
• 氢受体数：
  4

安全信息

• 危险等级：
  IRRITANT
• 海关编码：
  2924299090

反应信息

• 作为反应物：
  描述：

  FMOC-D-2-二氢茚基甘氨酸 、 4,6-二氯水杨醛 、 N-芴甲氧羰基-D-苯基甘氨酸 在 2,4,6-三甲基吡啶 、 (1-cyano-2-ethoxy-2-oxoethylidenaminooxy)dimethylaminomorpholinocarbenium hexafluorophosphate 、 哌啶 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 2.0h， 以68%的产率得到(R)-N-((R)-2-amino-2-oxo-1-phenylethyl)-2-((2,4-dichloro-6-hydroxybenzyl)amino)-2-(2,3-dihydro-1H-inden-2-yl)acetamide
  参考文献：
  名称：

  WO2022/150768

  摘要：

  公开号：

文献信息

• From a Helix to a Small Cycle: Metadynamics-Inspired αvβ6 Integrin Selective Ligands
  作者：Francesco Saverio Di Leva、Stefano Tomassi、Salvatore Di Maro、Florian Reichart、Johannes Notni、Abha Dangi、Udaya Kiran Marelli、Diego Brancaccio、Francesco Merlino、Hans-Jürgen Wester、Ettore Novellino、Horst Kessler、Luciana Marinelli

  DOI：10.1002/anie.201803250

  日期：2018.10.26

  low‐molecular‐weight ligands of this receptor is still in great demand. Here, a metadynamics‐driven design strategy allowed us to successfully convert a helical nonapeptide into a cyclic pentapeptide (6) showing remarkable potency and αvβ6 specificity. NMR and docking studies elucidated the reasons for the high affinity and selectivity of this compound, setting the ground for the rational design of new αvβ6‐specific

  刚刚获得RGD认可的αvβ6整联蛋白已成为癌症诊断和治疗的主要目标。因此，对这种受体的选择性，低分子量配体的开发仍然有很大的需求。在这里，一种由元动力学驱动的设计策略使我们能够成功地将螺旋九肽转换为环状五肽（6），显示出显着的效能和αvβ6特异性。NMR和对接研究阐明了该化合物具有高亲和力和选择性的原因，为合理设计新的αvβ6特异性小肽甚至拟肽化合物奠定了基础。体内PET成像研究表明6在医疗应用中的潜在用途。
• MACROCYCLIC COMPOUNDS FOR INHIBITION OF TUMOR NECROSIS FACTOR ALPHA
  申请人：Lee Jinbo

  公开号：US20100152099A1

  公开（公告）日：2010-06-17

  The invention provides macrocyclic compounds and methods for their synthesis and use. In particular, the invention provides macrocyclic compounds that modulate the activity of tumor necrosis factor alpha and/or are useful in the treatment of medical conditions, such as, rheumatoid arthritis, psoriasis, and asthma.

  该发明提供了大环化合物及其合成和使用方法。具体而言，该发明提供了调节肿瘤坏死因子α活性和/或用于治疗医学状况（如类风湿性关节炎、银屑病和哮喘）的大环化合物。
• ¹⁸F-Trifluoroborate Derivatives of [Des-Arg¹⁰]Kallidin for Imaging Bradykinin B1 Receptor Expression with Positron Emission Tomography
  作者：Zhibo Liu、Guillaume Amouroux、Zhengxing Zhang、Jinhe Pan、Navjit Hundal-Jabal、Nadine Colpo、Joseph Lau、David M. Perrin、François Bénard、Kuo-Shyan Lin

  DOI：10.1021/acs.molpharmaceut.5b00003

  日期：2015.3.2

  Bradykinin B1 receptor (B1R) is involved in pain and inflammation pathways and is upregulated in inflamed tissues and cancer. Due to its minimal expression in healthy tissues, B1R is an attractive target for the development of therapeutic agents to treat inflammation, chronic pain, and cancer. The goal of this study is to synthesize and compare two F-18-labeled peptides derived from potent B1R antagonists B9858 and B9958 for imaging B1R expression with positron emission tomography (PET). Azidoacetyl-B9858 2 and azidoacetyl-B9958 3 were synthesized by a solid-phase approach and subsequently clicked to ammoniomethyl-trifluoroborate (AmBF3)-conjugated alkyne 1 to obtain AmBF3-B9858 and AmBF3-B9958, respectively. AmBF3-B9858 and AmBF3-B9958 bound B1R with high affinity, with Ki values at 0.09 +/- 0.08 and 0.46 +/- 0.03 nM, respectively, as measured by in vitro competition binding assays. F-18 labeling was performed via an F-18-F-19 isotope exchange reaction. The radiofluorinated tracers were obtained within a synthesis time of 30 min and with 23-32% non-decay-corrected radiochemical yield, >99% radiochemical purity, and 43-87 GBq/mu mol specific activity at the end of the synthesis. PET imaging and biodistribution studies were carried out in mice bearing both B1R-positive (B1R(+)) HEK293T::hB1R and B1R-negative (B1R(-)) HEK293T tumors. Both tracers cleared rapidly from most organs/tissues, mainly through the renal pathway. High uptake in B1R(+) tumors (F-18-AmBF3-B9858: 3.94 +/- 1.24% ID/g, tumor-to-muscle ratio 21.3 +/- 4.33; F-18-AmBF3-B9958: 4.20 +/- 0.98% ID/g, tumor-to-muscle ratio 48.6 +/- 10.7) was observed at 1 h postinjection. These results indicate that F-18-AmBF3-B9858 and F-18-AmBF3-B9958 are promising agents for the in vivo imaging of B1R expression with PET.
• Methods for synthesis of encoded libraries
  申请人：Morgan Barry

  公开号：US20070042401A1

  公开（公告）日：2007-02-22

  The present invention provides a method of synthesizing libraries of molecules which include an encoding oligonucleotide tag.
• Methods for identifying compounds of interest using encoded libraries
  申请人：Morgan Barry

  公开号：US20070224607A1

  公开（公告）日：2007-09-27

  The present invention provides a method for identifying a compound of interest by screening libraries of molecules which include an encoding oligonucleotide tag.